HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

HOOKIPA Pharma (NASDAQ: HOOK) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York. Key highlights include:

1. Management team will host one-on-one meetings with investors.

2. CEO Dr. Malte Peters will participate in a Fireside Chat on September 9, 2024, at 1:30 p.m. ET.

3. The Fireside Chat will be available via webcast with a replay accessible for 90 days.

4. HOOKIPA is developing a new class of immunotherapeutics based on its proprietary arenavirus platform.

This event provides an opportunity for investors to gain insights into HOOKIPA's innovative approach to immunotherapy and its potential impact on the biotechnology sector.

NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of the management team will participate in the H.C. Wainwright 26^th Annual Global Investment Conference, taking place from September 9th-11th, 2024 in New York.

Dr. Malte Peters, Hookipa’s Chief Executive Officer, and Terry Coelho, Executive Vice President & Chief Financial Officer will be hosting one-on-one meetings with investors during the conference. In addition, Dr. Peters will participate in a Fireside Chat on Monday, September 9, 2024 at 1:30 p.m. ET.

The fireside chat will be available via webcast through the following link: https://journey.ct.events/view/a5640121-61ef-4c2b-8017-b6b346ca2547

A replay of this webcast will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. Archived replays will be accessible for 90 days following each event.

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead. 

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
chuck@lifesciadvisors.com

FAQ

When is HOOKIPA Pharma (HOOK) participating in the H.C. Wainwright Global Investment Conference?

HOOKIPA Pharma (HOOK) is participating in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York.

Who from HOOKIPA Pharma (HOOK) will be presenting at the conference?

Dr. Malte Peters, HOOKIPA's CEO, will participate in a Fireside Chat on September 9, 2024, at 1:30 p.m. ET. Additionally, Dr. Peters and Terry Coelho, Executive VP & CFO, will host one-on-one meetings with investors.

How can investors access HOOKIPA Pharma's (HOOK) Fireside Chat at the conference?

Investors can access HOOKIPA Pharma's Fireside Chat via webcast through a provided link. A replay will be available on the company's website for 90 days following the event.

What type of technology is HOOKIPA Pharma (HOOK) developing?

HOOKIPA Pharma is developing a new class of immunotherapeutics based on its proprietary arenavirus platform.